Navigation Links
1 step closer to a drug treatment for cystic fibrosis, MU professor says
Date:10/12/2010

COLUMBIA, Mo. A University of Missouri researcher believes his latest work moves scientists closer to a cure for cystic fibrosis, one of the world's most common fatal genetic diseases.

The Journal of Biological Chemistry has published findings by Tzyh-Chang Hwang, a professor in the School of Medicine's Department of Medical Pharmacology and Physiology and the Dalton Cardiovascular Research Center. The publication has been recognized as the "paper of the week" for the journal, meaning Hwang's work is considered to be in the top 1 percent of papers reviewed annually in terms of significance and overall importance.

Hwang's work focuses on the two most common genetic mutations among approximately 1,500 mutations found in patients with cystic fibrosis. These two mutations cause specific chloride channels in the cell, known as the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) chloride channels, to malfunction. This ultimately leads to repeated pneumonia, the primary cause of most deaths associated with cystic fibrosis.

"The normal function of a cell is to pass chloride ions across the cell membrane at a very fast speed," Hwang said. "We know some signaling molecules elicit this reaction, much like a hand signals an automatic water faucet to dispense water. But in the case of cystic fibrosis, that signal is no longer detected by the mutated channel protein. Through some mechanisms we still don't quite understand, malfunction of this channel protein eventually leads to bacterial infection in the lung, which is believed to be responsible for the most severe symptoms of cystic fibrosis."

The most recent study found that manipulating the sensor of the channel protein can significantly rectify the malfunction of the mutated channel, thus opening the door to a drug design that may eventually be a "real cure," Hwang said.

"We could help a lot of patients if we can utilize the power of computer simulations and structure-based drug design to discover new therapeutical reagents for cystic fibrosis, but it's very expensive to do this kind of research in an academic institute," Hwang said.


'/>"/>

Contact: Steven Adams
AdamsST@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert

Related biology news :

1. Plant scientists move closer to making any crop drought-tolerant
2. Solid oxide fuel cells getting closer to the market
3. Gene therapy a step closer to mass production
4. Research is getting closer to understanding critical nucleus in haze formation, prof says
5. Genome BC, Chile and Norway take another step closer to fully sequencing the salmon genome
6. Low-cost, ultra-fast DNA sequencing brings diagnostic use closer
7. For osteoporosis patients, exercise pill one step closer to reality
8. Bringing better grapes a step closer to reality
9. Cold fusion moves closer to mainstream acceptance
10. 1 step closer to closure
11. ESA and World Bank move toward closer collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... BRUNSWICK, N.J. , Jan. 11, 2017  Michael Johnson, co-founder ... Foundation Venture Capital Group, Inc., has been named to the elite ... Johnson, 27,  was one of 600 people in 20 fields nationwide ... four percent of the 15,000 applicants were selected. ... He is currently a PhD candidate ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at ... global leader in connected health and biometric measurement devices and services, will ... On display in A&D Medical,s special CES Exhibit Suite ... the ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... , ... January 18, 2017 , ... ... and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff ... past year and is planned for further growth in 2017. Extractable & Leachable ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... and paralysis, today announced that it has submitted a 510(k) to the FDA, ... that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers are ... Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including Pfizer, ... such as trial performance metrics, patient enrollment diversity, protocol optimization, and global site ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the ... paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue ... Bik joined uBiome in October 2016 from her previous position at Stanford University ...
Breaking Biology Technology: